Home workouts before transplant may boost strength in myeloma patients
NCT ID NCT05706766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an 8-week home-based exercise program, done before a stem cell transplant, can improve muscle strength and physical fitness in people with multiple myeloma. Thirty participants will either exercise via Zoom or continue normal activities. The goal is to see if prehabilitation helps patients feel stronger and recover more smoothly after transplant.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Prehabilitation aerobic and resistance exercise program
- What this could lead to
- If it works, this could show that a simple home exercise program before transplant helps patients feel stronger and recover faster.
- What could go wrong
- This is a small early trial with only 30 participants, so results may not apply to everyone. Exercise may not improve outcomes for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Over 18 years old. * All patients will have a diagnosis of multiple myeloma, referral to DFCI transplant team, and assigned to the autologous transplantation waiting list for a first transplant. * Planning to receive autologous stem cell transplant after 8 weeks with or without concurrent neoadjuvant treatments at Dana-Farber Cancer Institute. * Medical clearance to perform moderate-vigorous intensity aerobic and resistance exercise intervention and fitness testing by their treating physician or a certified clinical exercise physiologist. * Speak English. * Currently participate in less than or equal to 60 minutes of structured moderate-vigorous intensity exercise/week. * Willing to travel to Dana-Farber Cancer Institute for necessary data collection. * Ability to understand and the willingness to sign a written informed consent document. * The effects of exercise on the developing fetus are unknown. For this reason, women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately. Exclusion Criteria: * History of unstable angina, abnormal resting ECG and/or unstable angina or a heart attack in the previous month to allow safe completion of the cardiopulmonary exercise test (CPET) or VO2peak test. * Patients with known spinal instability, spinal cord compression or neurological deficits or contraindications that preclude exercise. * Those who have had recent (within six weeks) spinal surgery or other intervention surgery for pathological fractures. * Those deemed unsuitable to partake by the transplant or study team. * Patients at high-risk of impending pathologic fracture of a weight-bearing bone (including spine, hip/femur and humerus) as determined by physician. * Unable or unwilling to undertake an exercise program on a regular basis. * Pre-existing musculoskeletal or cardiorespiratory disease, or metabolic diseases that could exacerbate with exercise, in addition to other conditions deemed unsafe by physician. * Patients with other active malignancies requiring active therapy. * Participate in more than 60 minutes of structured moderate to vigorous intensity exercise/week. * Unable to travel to Dana-Farber Cancer Institute for necessary data collection. * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody combo aims to deepen myeloma responses
- Can a stronger drug cocktail give older myeloma patients a better start?
- Can adding methotrexate to steroids tame a dangerous transplant complication?
- Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
- Can a t-cell engager rescue myeloma that outsmarted CAR-T?
- Can myeloma treatment work without steroids?